<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647437</url>
  </required_header>
  <id_info>
    <org_study_id>13-1495</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02647437</nct_id>
  </id_info>
  <brief_title>Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia</brief_title>
  <official_title>Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Levetiracetam (LEV: (S)-Î±-ethyl-2-oxo-pyrrolidine acetamide) is an
      anticonvulsant/antiepileptic drug. The specific aim of this study is to assess the efficacy
      of low-dose LEV in reducing hippocampal activity in schizophrenia. The investigators also
      hypothesize that LEV will improve neurocognition in patients with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LEV is typically administered in twice-daily doses of 500-1500 mg for the treatment of
      epilepsy; these doses are generally well tolerated (Patsalos, 2000). Most relevant to the
      proposed study, LEV (125 mg twice-daily, two week administration) reduces hippocampal
      hyperactivity and improves cognition in patients with mild cognitive impairment (MCI) (Bakker
      et al., 2012).

      The proposed study will administer 125 mg of immediate release LEV twice-daily for two weeks.
      This dose was chosen to potentially maximize efficacy while minimizing side effects. The
      proposed dose is substantially lower than the most common dose used clinically for epilepsy
      treatment of 3000 mg/day.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resting-state neuronal response</measure>
    <time_frame>2 weeks</time_frame>
    <description>Neuronal response (measured via functional magnetic resonance imaging, fMRI) in the hippocampus during rest</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function</measure>
    <time_frame>2 weeks</time_frame>
    <description>Cognitive function as measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Levetiracetam, Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 weeks of levetiracetam administration (125 mg pill, bid), followed by a 1-2 week washout, then 2 weeks of placebo pill administration (bid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Then Levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 weeks of placebo pill administration (bid), followed by a 1-2 week washout, then 2 weeks of levetiracetam administration (125 mg pill, bid).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <arm_group_label>Levetiracetam, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Levetiracetam</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Levetiracetam, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Levetiracetam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia or schizoaffective disorder

          -  Good general health

          -  Normal vital signs (blood pressure, pulse, cardiac, pulmonary, abdominal, neurological
             exam)

          -  Normal renal function (as assessed by a metabolic panel at screening if results
             current within three months are not already available)

        Exclusion Criteria:

          1. Substance abuse

          2. Significant neurological disorders

          3. Significant head trauma/injury

          4. Left-handedness

          5. Pregnancy

          6. MRI-specific exclusion criteria (e.g., claustrophobia, weight &gt; 450lbs, metal in the
             body)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Tregellas, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristina T Legget, Ph.D.</last_name>
    <phone>303-724-5809</phone>
    <email>kristina.legget@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina T Legget, Ph.D.</last_name>
      <phone>303-724-5809</phone>
      <email>kristina.legget@ucdenver.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

